Characterization of the Translocation Breakpoint Sequences of Two DEK-CAN Fusion Genes Present in T(6;9) Acute Myeloid Leukemia and a SET-CAN Fusion Gene Found in a Case of Acute Undifferentiated Leukemia
Overview
Oncology
Affiliations
The t(6;9) associated with a subtype of acute myeloid leukemia (AML) was shown to generate a fusion between the 3' part of the CAN gene on chromosome 9 and the 5' part of the DEK gene on chromosome 6. The same part of the CAN gene appeared to be involved in a case of acute undifferentiated leukemia (AUL) as well, where it was fused to the SET gene. Genomic sequences around the translocation breakpoint were determined in two t(6;9) samples and in the case of the SET-CAN fusion. Although coexpression of myeloid markers and terminal deoxynucleotidyl transferase was shown to be one of the characteristics of t(6;9) AML, no addition of random nucleotides at the translocation breakpoint could be found. In addition, the breakpoint regions did not reveal heptamer-nonamer sequences, purine-pyrimidine tracts, a chi-octamer motif, or Alu repeats. The sequence in which the translocation breakpoints occurred was enriched in A/T. Notably, the specific introns in which clustering of breakpoints occurs in DEK and CAN both contain a LINE-I element. As LINE-I elements occur with a moderate frequency in the human genome, the presence of such an element in both breakpoint regions may be more than coincidental and may play a role in the translocation process.
Rearrangements in Leukemia Patients: A Case Series From a Single Institution.
Choi Y, Min Y, Lee S, Choi J, Shin S Ann Lab Med. 2023; 44(4):335-342.
PMID: 38145892 PMC: 10961622. DOI: 10.3343/alm.2023.0301.
SET-CAN/NUP214 fusion gene in leukemia: general features and clinical advances.
Song J, Li H, Fan S Front Oncol. 2023; 13:1269531.
PMID: 37909026 PMC: 10613893. DOI: 10.3389/fonc.2023.1269531.
Shen Y, Yang D, Zhang R, Chen X, Ma Q, Wei J Front Oncol. 2023; 13:1256043.
PMID: 37901324 PMC: 10611484. DOI: 10.3389/fonc.2023.1256043.
SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.
Di Mambro A, Arroyo-Berdugo Y, Fioretti T, Randles M, Cozzuto L, Rajeeve V Oncogene. 2023; 42(50):3670-3683.
PMID: 37891368 PMC: 10709139. DOI: 10.1038/s41388-023-02840-1.
Acute Undifferentiated Leukemia With a Balanced t(5;10)(q35;p12) Resulting in Fusion of With .
Panagopoulos I, Andersen K, Wik H, Tandsaether M, Micci F, Heim S Cancer Genomics Proteomics. 2023; 20(4):354-362.
PMID: 37400142 PMC: 10320562. DOI: 10.21873/cgp.20387.